长QT综合征遗传基质、QTc间期与心律失常风险的交互作用
该研究基于1,710例长QT综合征患者中位随访7.1年的数据,分析QTc间期与基因型对5年危及生命心律失常事件(LAE)风险的联合影响。线性模型拟合最佳,QTc每增加10 ms所有基因型LAE风险增加15%;LQT2和LQT3在任何QTc下风险分别较LQT1增加130%和157%。仅纳多洛尔显著降低所有基因型心律失常风险(HR 0.38,95%CI 0.15–0.93,P=0.03)。
要点
- QTc每增加10 ms,所有基因型5年LAE风险增加15%。
- LQT2和LQT3在任何QTc水平下风险分别较LQT1增加130%和157%。
- 仅纳多洛尔显著降低所有基因型LAE风险(HR 0.38,95%CI 0.15–0.93,P=0.03)。
核心结论
- 基于QTc和基因型的风险分层可细化长QT综合征患者5年心律失常风险评估。
- 纳多洛尔在降低所有基因型LAE风险方面优于未治疗。
研究设计与样本
- 回顾性分析1,710例长QT综合征患者,中位随访7.1年(IQR 2.7–13.4年)。
- 采用线性与立方样条模型比较QTc与事件风险关系,线性模型拟合最佳。
- 多变量Cox模型评估QTc和基因型对5年LAE风险的独立影响,并分析β受体阻滞剂疗效。
主要发现
- QTc每增加10 ms,所有基因型5年LAE风险增加15%。
- LQT2和LQT3在任何QTc持续时间下风险分别较LQT1增加130%和157%。
- 仅纳多洛尔显著降低所有基因型心律失常风险(HR 0.38,95%CI 0.15–0.93,P=0.03)。
关键数值与推荐
- 5年LAE风险估算基于QTc持续时间和基因型。
- 风险比:QTc每10 ms增量HR对应增加15%。
- 基因型风险比较:LQT2 vs LQT1风险增加130%,LQT3 vs LQT1增加157%。
- 纳多洛尔 vs 未治疗:HR 0.38(95%CI 0.15–0.93,P=0.03)。
临床怎么用
- 临床可结合QTc和基因型对长QT综合征患者进行5年LAE风险分层。
- 纳多洛尔可作为所有基因型长QT综合征患者降低心律失常风险的首选β受体阻滞剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long QT syndrome (LQTS) is a common inheritable arrhythmogenic disorder, often secondary to mutations in the KCNQ1, KCNH2, and SCN5A genes. The disease is characterized by a prolonged ventricular repolarization (QTc interval) that confers susceptibility to life-threatening arrhythmic events (LAEs). OBJECTIVES: This study sought to create an evidence-based risk stratification scheme to personalize the quantification of the arrhythmic risk in patients with LQTS. METHODS: Data from 1,710 patients with LQTS followed up for a median of 7.1 years (interquartile range [IQR]: 2.7 to 13.4 years) were analyzed to estimate the 5-year risk of LAEs based on QTc duration and genotype and to assess the antiarrhythmic efficacy of beta-blockers. RESULTS: The relationship between QTc duration and risk of events was investigated by comparison of linear and cubic spline models, and the linear model provided the best fit. The 5-year risk of LAEs while patients were off therapy was then calculated in a multivariable Cox model with QTc and genotype considered as independent factors. The estimated risk of LAEs increased by 15% for every 10-ms increment of QTc duration for all genotypes. Intergenotype comparison showed that the risk for patients with LQT2 and LQT3 increased by 130% and 157% at any QTc duration versus patients with LQT1. Analysis of response to beta-blockers showed that only nadolol reduced the arrhythmic risk in all genotypes significantly compared with no therapy (hazard ratio: 0.38; 95% confidence interval: 0.15 to 0.93; p = 0.03). CONCLUSIONS: The study provides an estimator of risk of LAEs in LQTS that allows a granular estimate of 5-year arrhythmic risk and demonstrate the superiority of nadolol in reducing the risk of LAEs in LQTS.
引用
- Mazzanti A, Maragna R, Vacanti G, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol. 2018. PMID: 29650123. doi:10.1016/j.jacc.2018.01.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。